AbCellera Biologics (ABCL) Non-cash Items (2021 - 2022)

AbCellera Biologics (ABCL) reported Non-cash Items of $113.4 million for Q4 2022, up 112960.82% on a YoY basis from N/an in Q4 2021, and up 12117.3% quarter-over-quarter from $928192.0 in Q3 2022.

AbCellera Biologics (ABCL) Non-cash Items (2021 - 2022) Analysis & Trends

AbCellera Biologics has reported Non-cash Items for 2 years, with the latest figure at $113.4 million in Q4 2022.

  • For the quarter ending Q4 2022, Non-cash Items rose 112960.82% year-over-year to $113.4 million; the trailing twelve-month figure through Dec 2022 stood at $113.4 million (up 112960.82% YoY), and the FY2022 full-year result was $113.4 million, up 112960.82% from the prior year.
  • Non-cash Items for Q4 2022 stood at $113.4 million, up from $928192.0 in the prior quarter.
  • The five-year high for Non-cash Items was $113.4 million in Q4 2022, with the low at $100300.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn -
7 Psyence Biomedical 227.32 Bn 227.31 Bn -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn
9 Abivax 91.71 Bn 91.71 Bn -
10 AbCellera Biologics 1.55 Bn 1.44 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2022 113.40 Mn
Dec 31, 2022 113.40 Mn
Sep 30, 2022 928,192.00
Sep 30, 2022 928,192.00
Jun 30, 2022 20.71 Mn
Jun 30, 2022 20.71 Mn
Mar 31, 2022 461,055.00
Mar 31, 2022 461,055.00
Dec 31, 2021 100,300.00
Dec 31, 2021 100,300.00
Sep 30, 2021 17.96 Mn
Sep 30, 2021 17.96 Mn
Jun 30, 2021 18.05 Mn
Jun 30, 2021 18.05 Mn
Mar 31, 2021 25.04 Mn
Mar 31, 2021 25.04 Mn